<DOC>
	<DOCNO>NCT00079287</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , vinorelbine , gemcitabine , docetaxel , paclitaxel , carboplatin , work different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know combination chemotherapy regimen effective treat non-small cell lung cancer . PURPOSE : This randomized phase III trial study well give vinorelbine together gemcitabine docetaxel work compare give paclitaxel together carboplatin treat patient stage IIIB , stage IV , recurrent non-small cell lung cancer .</brief_summary>
	<brief_title>Vinorelbine , Gemcitabine , Docetaxel Compared With Paclitaxel Carboplatin Treating Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare therapeutic effect vinorelbine , gemcitabine , docetaxel v paclitaxel carboplatin patient advance non-small cell lung cancer . - Compare overall survival patient treat regimen . Secondary - Compare response rate patient treat regimen . - Compare toxicity regimens patient . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive vinorelbine IV gemcitabine IV day 1 8 . Treatment repeat every 21 day 3 course . Patients receive docetaxel IV day 1 . Treatment repeat every 21 day 3 course . - Arm II : Patients receive carboplatin IV paclitaxel IV day 1 . Treatment repeat every 21 day 6 course . Patients follow 1 year . PROJECTED ACCRUAL : A total 400 patient ( 200 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm primary nonsmall cell lung cancer ( NSCLC ) meeting criterion 1 follow : Newly diagnose select stage IIIB ( T4 lesion due malignant pleural effusion ) disease Newly diagnose stage IV disease Recurrent disease prior surgery and/or radiotherapy The following cellular subtypes allow : Adenocarcinoma Large cell carcinoma Squamous cell carcinoma Unspecified carcinoma Measurable nonmeasurable disease CT scan , MRI , xray , physical examination , bone scintigraphy Pleural effusion , ascites , laboratory parameter allow evidence disease Disease must present outside area prior surgical resection Disease must present outside area prior radiotherapy OR new lesion document No know brain metastasis CT scan MRI within past 6 week No pleural pericardial effusion require treatment PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Hepatic Bilirubin ≤ 2 time upper limit normal ( ULN ) SGOT SGPT ≤ 2 time ULN Alkaline phosphatase ≤ 2 time ULN Renal Creatinine ≤ ULN Creatinine clearance ≥ 50 mL/min Cardiovascular No uncontrolled hypertension No unstable angina No congestive heart failure No myocardial infarction within past year No ventricular arrhythmia require medical intervention Other Not pregnant nursing Fertile patient must use effective contraception No prior allergic drug reaction attribute Cremophor polysorbate 80 No disorder associate lung cancer lifethreatening consequence No motor sensory neuropathy ≥ grade 2 No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer currently complete remission No uncontrolled diabetes PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy NSCLC Chemotherapy No prior systemic chemotherapy NSCLC Endocrine therapy No prior concurrent steroidtype hormonal therapy ( e.g. , ethinyl estradiol ) Radiotherapy See Disease Characteristics At least 3 week since prior radiotherapy recover Surgery See Disease Characteristics At least 2 week since prior thoracic major surgery recover Other No prior concurrent azole antifungal therapy ( e.g. , ketoconazole , miconazole , itraconazole ) No prior concurrent macrolides ( e.g. , erythromycin clarithromycin ) No prior concurrent cyclosporine , terfenadine , benzodiazepine ( e.g. , diazepam , triazolam , midazolam ) , retinoids No prior concurrent calcium antagonist ( e.g. , diltiazem , nifedipine , verapamil )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2005</verification_date>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>